RA0040

antibody from Oursmab

Targeting: BTLA BTLA1, CD272

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0040

Provider

Oursmab

Product name

Tifcemalimab (Biosimilar Reference Antibody) (BTLA)

Antibody type

Monoclonal

Description

Tifcemalimab (TAB004/JS004) is a humanized IgG4 kappa monoclonal antibody targeting B- and T-lymphocyte attenuator (BTLA), an inhibitory immune checkpoint receptor expressed on T cells, B cells, and dendritic cells. It binds to BTLA to block its interaction with the ligand herpesvirus entry mediator (HVEM), thereby reversing immune suppression and enhancing anti-tumor immunity. It is being developed for cancer immunotherapy, often in combination with PD-1 inhibitors, for the treatment of advanced solid tumors.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.